• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.原发性前列腺癌的AR-V7生物标志物检测：分析验证和临床鉴定的持续挑战。
Cancer Treat Res Commun. 2021;28:100218. doi: 10.1016/j.ctarc.2020.100218. Epub 2020 Oct 9.
2
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.一种用于检测转移性去势抵抗性前列腺癌中雄激素受体剪接变体-7蛋白表达的新型免疫组织化学检测方法的分析验证和临床鉴定
Eur Urol. 2016 Oct;70(4):599-608. doi: 10.1016/j.eururo.2016.03.049. Epub 2016 Apr 23.
3
AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.AR-V7作为三个拉丁美洲国家阿比特龙/恩杂鲁胺治疗耐药生物标志物的假设性成本节约分析
Oncologist. 2020 Dec;25(12):e1990-e1995. doi: 10.1634/theoncologist.2020-0043. Epub 2020 Aug 19.
4
AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.外周血循环肿瘤细胞中 AR-V7 的检测：阿比特龙和恩杂鲁胺治疗相关预后的关联
Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.
5
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.对符合阿比特龙或恩杂鲁胺治疗条件的转移性去势抵抗性前列腺癌患者进行AR-V7检测的成本节约分析。
Prostate. 2016 Dec;76(16):1484-1490. doi: 10.1002/pros.23232. Epub 2016 Jul 12.
6
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.雄激素受体剪接变异体-7 作为去势敏感性前列腺癌临床反应生物标志物的评估。
Clin Cancer Res. 2022 Aug 15;28(16):3509-3525. doi: 10.1158/1078-0432.CCR-22-0851.
7
AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.循环肿瘤细胞簇中的AR-V7作为去势抵抗性前列腺癌患者醋酸阿比特龙和恩杂鲁胺治疗的预测生物标志物。
Prostate. 2018 Jun;78(8):576-582. doi: 10.1002/pros.23501. Epub 2018 Mar 5.
8
Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.针对反应剪接变异优化的雄激素受体调节剂：Galeterone 对比恩杂鲁胺治疗雄激素受体剪接变异体 7 表达的转移性去势抵抗性前列腺癌的 3 期随机试验。
Eur Urol. 2019 Dec;76(6):843-851. doi: 10.1016/j.eururo.2019.08.034. Epub 2019 Sep 18.
9
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.转移性去势抵抗性前列腺癌患者全血 RNA 中的 AR-V7 转录本与醋酸阿比特龙的反应相关。
J Urol. 2017 Jan;197(1):135-142. doi: 10.1016/j.juro.2016.06.094. Epub 2016 Jul 17.
10
[AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer].[AR-V7雄激素受体变体作为用于治疗去势抵抗性转移性前列腺癌的雄激素受体靶向药物反应的预测指标]
Klin Onkol. 2017 Winter;31(1):9-14. doi: 10.14735/amko20189.

引用本文的文献

1
Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer.雄激素受体剪接变异体-7 作为去势敏感性前列腺癌临床反应生物标志物的评估。
Clin Cancer Res. 2022 Aug 15;28(16):3509-3525. doi: 10.1158/1078-0432.CCR-22-0851.

本文引用的文献

1
Antibody selection influences the detection of AR-V7 in primary prostate cancer.抗体选择会影响原发性前列腺癌中 AR-V7 的检测。
Cancer Treat Res Commun. 2020;24:100186. doi: 10.1016/j.ctarc.2020.100186. Epub 2020 Jun 23.
2
Detecting predictive androgen receptor modifications in circulating prostate cancer cells.检测循环前列腺癌细胞中具有预测性的雄激素受体修饰
Oncotarget. 2015 Apr 23;10(41):4213-4223. doi: 10.18632/oncotarget.3925. eCollection 2019 Jun 25.
3
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.雄激素受体剪接变体 7 与高危去势抵抗性前列腺癌激素治疗抵抗的前瞻性多中心验证：PROPHECY 研究。
J Clin Oncol. 2019 May 1;37(13):1120-1129. doi: 10.1200/JCO.18.01731. Epub 2019 Mar 13.
4
If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.如果这是真的，这意味着什么？最终用户抗体验证如何促进对生物学和疾病的深入了解。
Asian J Urol. 2019 Jan;6(1):10-25. doi: 10.1016/j.ajur.2018.11.006. Epub 2018 Dec 12.
5
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer.雄激素受体剪接变异体-7 的表达随着前列腺癌的去势抵抗而出现。
J Clin Invest. 2019 Jan 2;129(1):192-208. doi: 10.1172/JCI122819. Epub 2018 Nov 26.
6
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.评估核定位雄激素受体剪接变体 7 在循环肿瘤细胞中作为去势抵抗性前列腺癌预测性生物标志物的有效性。
JAMA Oncol. 2018 Sep 1;4(9):1179-1186. doi: 10.1001/jamaoncol.2018.1621.
7
Nuclear Circulating Tumor Cell Androgen Receptor Variant 7 in Castration-Resistant Prostate Cancer: The Devil Is in the Detail.去势抵抗性前列腺癌中的核循环肿瘤细胞雄激素受体变异体7：细节决定成败
JAMA Oncol. 2018 Sep 1;4(9):1187-1188. doi: 10.1001/jamaoncol.2018.1615.
8
Neoadjuvant-Intensive Androgen Deprivation Therapy Selects for Prostate Tumor Foci with Diverse Subclonal Oncogenic Alterations.新辅助强化雄激素剥夺治疗选择具有不同亚克隆致癌改变的前列腺肿瘤病灶。
Cancer Res. 2018 Aug 15;78(16):4716-4730. doi: 10.1158/0008-5472.CAN-18-0610. Epub 2018 Jun 19.
9
Metastatic Prostate Cancer.转移性前列腺癌
N Engl J Med. 2018 Feb 15;378(7):645-657. doi: 10.1056/NEJMra1701695. Epub 2018 Feb 7.
10
Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.原发性前列腺癌中核AR-V7蛋白的过表达是接受辅助治疗的高危疾病男性患者的独立不良预后标志物。
Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.

AR-V7 biomarker testing for primary prostate cancer: The ongoing challenge of analytical validation and clinical qualification.

作者信息

Sowalsky Adam G, Sharp Adam, Trostel Shana Y, de Bono Johann S, Plymate Stephen R

机构信息

Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, NIH, Bethesda, MD, United States.

The Institute of Cancer Research, London, United Kingdom; The Royal Marsden, London, United Kingdom.

出版信息

Cancer Treat Res Commun. 2021;28:100218. doi: 10.1016/j.ctarc.2020.100218. Epub 2020 Oct 9.

DOI:10.1016/j.ctarc.2020.100218
PMID:33516656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8114102/
Abstract
摘要